Cumberland Pharmaceuticals Q1 revenue up 5%; to sell FDA‑approved brands to Apotex for $100 mln

Cumberland Pharmaceuticals Inc.

Cumberland Pharmaceuticals Inc.

CPIX

0.00


Overview

  • US specialty pharma firm's Q1 revenue rose 5% yr/yr, excluding prior-year milestone payment

  • Adjusted loss per share for Q1 was $0.13

  • Company to sell FDA-approved brands to Apotex for $100 mln, pending shareholder approval


Outlook

  • Company expects to focus on advancing pipeline after divesting FDA-approved brands to Apotex

  • Cumberland to retain development programs and majority ownership in Cumberland Emerging Technologies post-transaction

  • Company highlights ongoing clinical trials for ifetroban in DMD, SSc, and IPF with regulatory milestones pending


Result Drivers

  • PRODUCT PORTFOLIO - Q1 revenue growth was driven by sales from FDA-approved brands including Sancuso, Vibativ, Talicia, Kristalose and Caldolor

  • STRATEGIC TRANSACTION - Co announced agreement to sell its FDA-approved brands to Apotex for $100 mln, aiming to focus on pipeline development

  • PIPELINE FOCUS - Co highlighted progress in clinical programs for ifetroban, including Fast Track Designation from the FDA.


Company press release: ID:nPn2F6vNra


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q1 Revenue

$9.10 mln

Q1 Adjusted EPS

-$0.13


Analyst Coverage

  • The one available analyst rating on the shares is "hold"

  • The average consensus recommendation for the pharmaceuticals peer group is "buy."


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.